The MedImmune-backed glaucoma treatment developer aims to raise up to $86.3m from its initial public offering, as well as an additional $46m in convertible debt.
Inotek Pharmaceuticals, a US-based developer of small molecule drugs for glaucoma, is planning to raise up to $132m from an initial public offering and convertible debt offering.
Inotek, which is backed by investors including MedImmune Ventures, biotechnology research company MedImmune’s corporate venturing unit, filed yesterday to raise up to $86.3m from an IPO on Nasdaq and $46m from a concurrent offering of convertible notes.
Founded in 1999, Inotek aims to begin a Phase 3 clinical trial in 2015 for its…
